genedrive plc (GDR) - Total Liabilities
Based on the latest financial reports, genedrive plc (GDR) has total liabilities worth GBX1.38 Million GBX (≈ $167.54 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See GDR net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
genedrive plc - Total Liabilities Trend (2006–2025)
This chart illustrates how genedrive plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see genedrive plc total assets.
genedrive plc Competitors by Total Liabilities
The table below lists competitors of genedrive plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tavistock Investments Plc
LSE:TAVI
|
UK | GBX12.56 Million |
|
Shearwater Group plc
LSE:SWG
|
UK | GBX20.10 Million |
|
Orchard Funding Group PLC
LSE:ORCH
|
UK | GBX49.90 Million |
|
CleanTech Lithium plc
LSE:CTL
|
UK | GBX18.39 Million |
|
Cambridge Cognition Holdings Plc
LSE:COG
|
UK | GBX9.40 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.48 Million |
|
Lexington Gold Ltd
LSE:LEX
|
UK | GBX631.23K |
|
Virgin Wines UK PLC
LSE:VINO
|
UK | GBX18.50 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down genedrive plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See genedrive plc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how genedrive plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for genedrive plc (2006–2025)
The table below shows the annual total liabilities of genedrive plc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX1.38 Million ≈ $167.54 |
-4.44% |
| 2024-06-30 | GBX1.44 Million ≈ $175.33 |
-41.57% |
| 2023-06-30 | GBX2.47 Million ≈ $300.04 |
+144.16% |
| 2022-06-30 | GBX1.01 Million ≈ $122.89 |
-21.40% |
| 2021-06-30 | GBX1.28 Million ≈ $156.35 |
-90.69% |
| 2020-06-30 | GBX13.79 Million ≈ $1.68K |
+41.71% |
| 2019-06-30 | GBX9.73 Million ≈ $1.18K |
+16.66% |
| 2018-06-30 | GBX8.35 Million ≈ $1.02K |
-3.02% |
| 2017-06-30 | GBX8.61 Million ≈ $1.05K |
+6.20% |
| 2016-06-30 | GBX8.10 Million ≈ $985.90 |
+25.67% |
| 2015-06-30 | GBX6.45 Million ≈ $784.54 |
+71.86% |
| 2014-06-30 | GBX3.75 Million ≈ $456.51 |
+86.02% |
| 2013-06-30 | GBX2.02 Million ≈ $245.41 |
+25.67% |
| 2012-06-30 | GBX1.60 Million ≈ $195.28 |
-1.35% |
| 2011-06-30 | GBX1.63 Million ≈ $197.96 |
-19.73% |
| 2010-06-30 | GBX2.03 Million ≈ $246.63 |
-35.77% |
| 2009-06-30 | GBX3.16 Million ≈ $383.99 |
+444.14% |
| 2008-06-30 | GBX580.00K ≈ $70.57 |
-21.83% |
| 2007-06-30 | GBX742.00K ≈ $90.28 |
+88.32% |
| 2006-06-30 | GBX394.00K ≈ $47.94 |
-- |
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more